Judgment of the General Court of 10 November 2021 – Stada Arzneimittel v EUIPO – Pfizer (RUXYMLA)
(Case T-248/20) 1
(EU trade mark – Opposition proceedings – Application for the EU word mark RUXYMLA – Earlier EU word mark RUXIMERA – Relative ground for refusal – Likelihood of confusion – Similarity of the signs – Article 8(1)(b) of Regulation (EU) 2017/1001)
Language of the case: English
Parties
Applicant: Stada Arzneimittel AG (Bad Vilbel, Germany) (represented by: J.-C. Plate and R. Kaase, lawyers)
Defendant: European Union Intellectual Property Office (represented by: D. Gája, acting as Agent)
Other party to the proceedings before the Board of Appeal of EUIPO, intervener before the General Court: Pfizer Inc. (New York, New York, United States) (represented by: V. von Bomhard and J. Fuhrmann, lawyers)
Re:
Action brought against the decision of the Fourth Board of Appeal of EUIPO of 13 February 2020 (Case R 1878/2019-4), relating to opposition proceedings between Pfizer and Stada Arzneimittel.
Operative part of the judgment
The Court:
Dismisses the action;
Orders Stada Arzneimittel AG to pay the costs.
____________
1     OJ C 209, 22.6.2020.